eteplirsen

Controversy surrounds Exondys 51 approval: What to knowNew medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
FDA approves first drug for Duchenne muscular dystrophyEven though an FDA panel recommended against approving a new drug to treat Duchenne muscular dystrophy in April, the agency granted accelerated approval to eteplirsen injection (Exondys 51, Sarepta Therapeutics) in mid-September.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching